Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Autoimmune, and Cardiovascular Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PLA2G10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PLA2G10 Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native fold. |
View PLA2G10 Products |
| Gene Delivery | PLA2G10 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View PLA2G10 Products |
| Benchmark Ab | Anti-PLA2G10 Benchmark Antibody Recombinant positive control antibody for binding and neutralization assays. |
View PLA2G10 Products |
| Validator | PLA2G10 siRNA Set For target knockdown verification in functional cell-based assays. |
View PLA2G10 Products |
| Related Target A | PLA2G2A Secretory phospholipase A2 Group IIA; critical for selectivity and counter-screening panels. |
View PLA2G2A Products |
| Related Target B | PLA2G5 Secretory phospholipase A2 Group V; shares functional overlap in lipid mediator generation. |
View PLA2G5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-target / Selectivity Screening | PLA2G2A, PLA2G5, and PLA2G10 homolog panel proteins strictly verified by mass spec and purity assays. |
| Conformational Integrity (8 Disulfide Bonds) | HEK293 mammalian expression ensures correct disulfide bond folding and chaperone-mediated processing. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) available for assay standardization. |
| False Positives in Knockdown | Sequence-verified siRNA sets included for high-specificity target validation. |
Live PLA2G10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PLA2G10 (Group X secretory phospholipase A2) is gaining traction as researchers uncover its distinct role in lipid metabolism, inflammatory cascades, and tumor microenvironment modulation. Unlike other sPLA2 groups, PLA2G10 exhibits exceptionally high lipolytic activity toward phosphatidylcholine, making it a potent driver of arachidonic acid release. The race for PLA2G10 therapeutics is intensifying, with major players shifting focus from broad-spectrum sPLA2 inhibitors to isoform-selective small molecules and neutralizing monoclonal antibodies. As first-generation broad-spectrum therapies reach clinical reassessment, the next wave of R&D is targeting highly selective PLA2G10 inhibition to avoid systemic off-target toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Consortia | Asthma, Inflammatory Airway Diseases | Neutralization Assay (Need high-purity, natively folded PLA2G10 protein) |
| Small Molecule Inhibitors | Pharmaceutical Developers | Atherosclerosis, Coronary Artery Disease | Selectivity Assay (Need Mutant vs WT and Subfamily Homolog Panels) |
| Combination Therapies | Oncology Research Groups | Solid Tumors (Pancreatic, Colon) | Cell-based validation (Need Lentivirus for stable overexpression) |